Identification of HER2-over-expression, HER2-low-expression, and HER2-zero-expression statuses in breast cancer based on 18F-FDG PET/CT radiomics

Table 1 Clinicopathological characteristics of BC patients enrolled in internal institutions

Clinicopathologic Characteristic	Training set (n = 150)				Independent validation set (n = 65)
Clinicopathologic Characteristic	HER2-over (n = 52)	HER2-low (n = 65)	HER2-zero (n = 33)	p	HER2-over (n = 27)	HER2-low (n = 31)	HER2-zero (n = 7)	p
Age	50.79 ± 11.05	52.8 ± 12.46	52.36 ± 13.31	0.660	54.00 ± 10.62	53.71 ± 11.69	60.57 ± 13.0	0.341
SUVmax	11.41 ± 5.67	10.96 ± 6.30	11.14 ± 5.76	0.921	11.91 ± 4.98	10.16 ± 4.90	10.83 ± 6.74	0.436
SUVmean	6.55 ± 3.35	6.60 ± 3.72	6.66 ± 3.91	0.983	7.10 ± 2.83	6.12 ± 2.84	6.12 ± 3.81	0.425
ER				0.001				0.036
Positive	23(15.3%)	51(34.0%)	22(14.7%)		16(24.6%)	26(40.0%)	3(4.6%)
Negative	29(19.3%)	14(9.3%)	11(7.3%)		11(16.9%)	5(7.7%)	4(6.2%)
PR				< 0.001				0.001
Positive	14(9.3%)	45(30.0%)	18(12.0%)		19(29.2%)	23(35.4%)	2(3.1%)
Negative	38(25.3%)	20(13.3%)	15(10.0%)		8(12.3%)	8(12.3%)	5(7.7%)
Ki-67				0.058				0.731
≥ 14	50(33.3%)	65(43.3%)	30(20.0%)		26(40.0%)	29(44.6%)	7(10.8%)
< 14	2(1.3%)	0(0%)	3(2.0%)		1(1.5%)	2(3.1%)	0(0%)

Abbreviations: ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; SUV: standardized uptake value

ISSN: 1470-7330